Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study

[1]  T. Yoshii,et al.  Current concept of stress fractures with an additional category of atypical fractures: a perspective review with representative images , 2021, Therapeutic advances in endocrinology and metabolism.

[2]  T. Rachner,et al.  Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  A. Riddick,et al.  Evaluation and management of atypical femoral fractures: an update of current knowledge , 2021, European Journal of Orthopaedic Surgery & Traumatology.

[4]  M. Aapro,et al.  BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Shingo Sato,et al.  Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report , 2020, Journal of bone oncology.

[6]  T. Yoshii,et al.  Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in "typical" atypical subtrochanteric femoral fracture: A proposed theory of atypical femoral fracture subtypes. , 2020, Bone.

[7]  R. Eastell,et al.  Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society , 2019, The Journal of clinical endocrinology and metabolism.

[8]  T. Yoshii,et al.  Potential bone fragility of mid-shaft atypical femoral fracture: Biomechanical analysis by a CT-based nonlinear finite element method. , 2019, Injury.

[9]  K. Kinowaki,et al.  Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review , 2019, BMC Cancer.

[10]  I. Makhoul,et al.  Atypical femoral fractures from bisphosphonate in cancer patients – Review , 2019, Journal of bone oncology.

[11]  W. B. Edwards,et al.  Influence of geometry on proximal femoral shaft strains: Implications for atypical femoral fracture. , 2018, Bone.

[12]  Jacques P. Brown,et al.  Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  R. Eastell,et al.  Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. , 2017, Bone.

[14]  A. Okawa,et al.  Location of atypical femoral fracture can be determined by tensile stress distribution influenced by femoral bowing and neck-shaft angle: a CT-based nonlinear finite element analysis model for the assessment of femoral shaft loading stress. , 2017, Injury.

[15]  J. Myong,et al.  Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center , 2017, Osteoporosis International.

[16]  P. Boland,et al.  Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. , 2017, The oncologist.

[17]  G. Hortobagyi,et al.  Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  T. Yong,et al.  Atypical femoral fracture in a patient treated with denosumab , 2015, Journal of Bone and Mineral Metabolism.

[19]  S. Morshed,et al.  Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. , 2014, The Journal of bone and joint surgery. American volume.

[20]  A. Okawa,et al.  Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: Mechanical analysis by the CT-based finite element method. , 2014, Injury.

[21]  Peter Pivonka,et al.  Femoral shaft strains during daily activities: Implications for atypical femoral fractures. , 2014, Clinical biomechanics.

[22]  A. Okawa,et al.  Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly Japanese: a case series , 2014, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[23]  G. Heyburn,et al.  Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. , 2014, Bone.

[24]  G. Scagliotti,et al.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors , 2014, Supportive Care in Cancer.

[25]  J. Schilcher,et al.  Atypical fracture of the femur in a patient using denosumab – a case report , 2014, Acta orthopaedica.

[26]  L. Fallowfield,et al.  Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid , 2012, Clinical Cancer Research.

[27]  B. Ettinger,et al.  Clinical correlates of atypical femoral fracture. , 2012, Bone.

[28]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  M. Hameed,et al.  Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. , 2011, The Journal of bone and joint surgery. American volume.

[30]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[31]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[33]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[36]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[37]  P. Tarassoff,et al.  Avascular necrosis of the jaws: risk factors in metastatic cancer patients. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[38]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[39]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.